161 related articles for article (PubMed ID: 23877991)
41. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
[TBL] [Abstract][Full Text] [Related]
42. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
43. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
44. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
45. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1971-3. PubMed ID: 19609501
[No Abstract] [Full Text] [Related]
46. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
47. [Insulin glargine--a systematic review of clinical studies. No documented advantages with Lantus compared to NPH insulin].
Björck Linné A; Liedholm H
Lakartidningen; 2004 Jul; 101(30-31):2402-7. PubMed ID: 15314935
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
49. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
Hershon KS; Blevins TC; Mayo CA; Rosskamp R
Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
[TBL] [Abstract][Full Text] [Related]
50. The association of long-acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population-based cohort study.
Brunetti VC; Yu OHY; Platt RW; Filion KB
Diabetes Obes Metab; 2022 Nov; 24(11):2169-2181. PubMed ID: 35726454
[TBL] [Abstract][Full Text] [Related]
51. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
Yeldandi RR; Lurie A; Baldwin D
Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
[TBL] [Abstract][Full Text] [Related]
52. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
[TBL] [Abstract][Full Text] [Related]
53. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
[TBL] [Abstract][Full Text] [Related]
54. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.
White NH; Chase HP; Arslanian S; Tamborlane WV;
Diabetes Care; 2009 Mar; 32(3):387-93. PubMed ID: 19106380
[TBL] [Abstract][Full Text] [Related]
55. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis.
Pollex E; Moretti ME; Koren G; Feig DS
Ann Pharmacother; 2011 Jan; 45(1):9-16. PubMed ID: 21205954
[TBL] [Abstract][Full Text] [Related]
56. Initiation of four basal insulins and subsequent treatment modification in people treated for type 2 diabetes in the United Kingdom: Changes over the period 2003-2018.
Brunetti VC; Yu OHY; Platt RW; Filion KB
Diabet Med; 2021 Aug; 38(8):e14603. PubMed ID: 34021511
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
58. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.
Caires de Souza AL; de Assis Acurcio F; Guerra Júnior AA; Rezende Macedo do Nascimento RC; Godman B; Diniz LM
Appl Health Econ Health Policy; 2014 Feb; 12(1):19-32. PubMed ID: 24385261
[TBL] [Abstract][Full Text] [Related]
59. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
60. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
